Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable ?Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

Beksac, MeralSeval, Guldane CengizPaydas, SemraTuglular, Tulin FiratliArslan, OnderGoker, HakanKaynar, Leylagul2024-06-122024-06-1220192152-26502152-2669https://doi.org/10.1016/j.clml.2019.09.402https://hdl.handle.net/20.500.14551/20752[Abstract Not Available]en10.1016/j.clml.2019.09.402info:eu-repo/semantics/closedAccessElotuzumabImmunomodulatory DrugsMultiple MyelomaElotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable ?Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From TurkeyConference Object1910E242E243Q3WOS:000491229800399